plexxo 100mg tableta
desitin arzneimittel gmbh, hamburg array - 9440 lamotrigin - tableta - 100mg - lamotrigin
plexxo 50mg tableta
desitin arzneimittel gmbh, hamburg array - 9440 lamotrigin - tableta - 50mg - lamotrigin
timonil retard 150mg tableta s prodlouženým uvolňováním
desitin arzneimittel gmbh, hamburg array - 1676 karbamazepin - tableta s prodlouženým uvolňováním - 150mg - karbamazepin
timonil retard 300mg tableta s prodlouženým uvolňováním
desitin arzneimittel gmbh, hamburg array - 1676 karbamazepin - tableta s prodlouženým uvolňováním - 300mg - karbamazepin
timonil retard 600mg tableta s prodlouženým uvolňováním
desitin arzneimittel gmbh, hamburg array - 1676 karbamazepin - tableta s prodlouženým uvolňováním - 600mg - karbamazepin
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - jiná antiepileptika - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.
tegretol cr 200mg tableta s prodlouženým uvolňováním
novartis s.r.o., praha array - 1676 karbamazepin - tableta s prodlouženým uvolňováním - 200mg - karbamazepin
tegretol cr 400mg tableta s prodlouženým uvolňováním
novartis s.r.o., praha array - 1676 karbamazepin - tableta s prodlouženým uvolňováním - 400mg - karbamazepin
blincyto
amgen europe b.v. - blinatumomab - prekurzorová buněčná lymfoblastická leukémie-lymfom - antineoplastická činidla - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.